The Largest LOE Event In US Pharma History

By Dean Rudge

Patent Trolls

Ahead of the first biosimilar Humira product set to launch in 365 days, this article provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

The arrival of the first biosimilar is to mark a watershed moment for industry, as the anti-tumor necrosis factor giant – the flagbearer in the treatment of inflammatory diseases like rheumatoid arthritis and Crohn’s disease – finally loses patent protection.

Explore how the largest loss of exclusivity event in the history of the US pharma market will usher in a new era of much-needed biosimilar competition for anti-TNF biologics.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online

West Pharmaceutical Services, Inc.